[go: up one dir, main page]

ECSP10010249A - Tratamiento de cardiopatías usando -bloqueantes - Google Patents

Tratamiento de cardiopatías usando -bloqueantes

Info

Publication number
ECSP10010249A
ECSP10010249A EC2010010249A ECSP10010249A ECSP10010249A EC SP10010249 A ECSP10010249 A EC SP10010249A EC 2010010249 A EC2010010249 A EC 2010010249A EC SP10010249 A ECSP10010249 A EC SP10010249A EC SP10010249 A ECSP10010249 A EC SP10010249A
Authority
EC
Ecuador
Prior art keywords
cardiopathies
blockers
treatment
reversing
animals
Prior art date
Application number
EC2010010249A
Other languages
English (en)
Inventor
Axel Schmidt
Gerald Beddies
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of ECSP10010249A publication Critical patent/ECSP10010249A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un procedimiento para revertir la remodelación cardiaca electrofisiológica de animales con cardiopatía. Más específicamente, el procedimiento incluye administrar a un animal que lo necesite un bloqueante de adrenoceptores .
EC2010010249A 2007-12-27 2010-06-14 Tratamiento de cardiopatías usando -bloqueantes ECSP10010249A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1689107P 2007-12-27 2007-12-27

Publications (1)

Publication Number Publication Date
ECSP10010249A true ECSP10010249A (es) 2010-07-30

Family

ID=40456577

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010249A ECSP10010249A (es) 2007-12-27 2010-06-14 Tratamiento de cardiopatías usando -bloqueantes

Country Status (19)

Country Link
US (1) US20100305213A1 (es)
EP (1) EP2234609A1 (es)
JP (1) JP2011507918A (es)
KR (1) KR20100102640A (es)
CN (1) CN101909612A (es)
AU (1) AU2008342250A1 (es)
BR (1) BRPI0821483A2 (es)
CA (1) CA2710665A1 (es)
CO (1) CO6300936A2 (es)
CR (1) CR11501A (es)
EC (1) ECSP10010249A (es)
IL (1) IL205870A0 (es)
MX (1) MX2010006443A (es)
NI (1) NI201000096A (es)
RU (1) RU2010131022A (es)
SV (1) SV2010003595A (es)
TW (1) TW200942227A (es)
WO (1) WO2009083177A1 (es)
ZA (1) ZA201003867B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113148A1 (zh) * 2012-01-30 2013-08-08 Lin Shuguang β3肾上腺素受体阻滞剂的抗肿瘤用途
WO2016138908A1 (en) 2015-03-03 2016-09-09 Saniona A/S Tesofensine, beta blocker combination formulation
US11235029B2 (en) 2017-03-09 2022-02-01 Temple University-Of The Commonwealth System of Higher Methods for treating heart failure with a TRKB agonist
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
CN110269938A (zh) * 2019-06-27 2019-09-24 山东省眼科研究所 一种减轻铜绿假单胞菌性角膜炎症的药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung

Also Published As

Publication number Publication date
RU2010131022A (ru) 2012-02-10
CR11501A (es) 2010-11-12
MX2010006443A (es) 2010-09-03
WO2009083177A1 (en) 2009-07-09
ZA201003867B (en) 2011-08-31
IL205870A0 (en) 2010-11-30
SV2010003595A (es) 2011-01-14
CA2710665A1 (en) 2009-07-09
JP2011507918A (ja) 2011-03-10
TW200942227A (en) 2009-10-16
CO6300936A2 (es) 2011-07-21
CN101909612A (zh) 2010-12-08
BRPI0821483A2 (pt) 2015-06-16
KR20100102640A (ko) 2010-09-24
AU2008342250A1 (en) 2009-07-09
US20100305213A1 (en) 2010-12-02
EP2234609A1 (en) 2010-10-06
NI201000096A (es) 2011-03-23

Similar Documents

Publication Publication Date Title
MX2015017865A (es) Compuestos de pirimidinodiona contra estados cardiacos.
CY1123255T1 (el) Σχημα δοσολογιας για εναν αγωνιστη υποδοχεα s1p
ECSP11010831A (es) Compuestos orgánicos para la cicatrización de heridas
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
EA201190280A1 (ru) Производные l-(пиперидин-4-ил)пиразола в качестве модуляторов gpr 119
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
JO3091B1 (ar) مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها
CY1115902T1 (el) Συνδυαστικη θεραπεια καρκινου με ανασταλτικες ενωσεις hps90
EA201300756A1 (ru) Композиции для осветления цвета кожи
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
CR9753A (es) Agente terapeutico para diabetes
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
MX2020011100A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
MX2013002390A (es) Tratamiento de infarto de miocardio usando antagonistas de tgf-beta.
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
BRPI0814286A2 (pt) Método melhorado para o tratamento de alimentos, rações e produtos agrícolas com um composto antifúngico de polieno
CR20110660A (es) Mezclas fungicidas
ECSP10010249A (es) Tratamiento de cardiopatías usando -bloqueantes